Anna I. Wernick

Anna I. Wernick

Auto-generated profile, based on publicly available information

Anna I. Wernick

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
MCMinee L. Choi
Minee L. Choi
ACAlexandre Chappard
Alexandre Chappard
BSBhanu P. Singh
Bhanu P. Singh
CMCatherine Maclachlan
Catherine Maclachlan
MRMargarida Rodrigues
Margarida Rodrigues
SGSonia Gandhi
Sonia Gandhi
Aggregation of alpha-synuclein (α-Syn) drives Parkinson’s disease (PD), although the initial stages of self-assembly and structural conversion have not been directly observed inside neurons. In this study, we tracked the intracellular conformational states of α-Syn using a single-molecule Förster resonance energy transfer (smFRET) biosensor, and we show here that α-Syn converts from a monomeric state into two distinct oligomeric states in neurons in a concentration-dependent and sequence-specific manner. Three-dimensional FRET-correlative light and electron microscopy (FRET-CLEM) revealed that intracellular seeding events occur preferentially on membrane surfaces, especially at mitochondrial membranes. The mitochondrial lipid cardiolipin triggers rapid oligomerization of A53T α-Syn, and cardiolipin is sequestered within aggregating lipid–protein complexes. Mitochondrial aggregates impair complex I activity and increase mitochondrial reactive oxygen species (ROS) generation, which accelerates the oligomerization of A53T α-Syn and causes permeabilization of mitochondrial membranes and cell death. These processes were also observed in induced pluripotent stem cell (iPSC)–derived neurons harboring A53T mutations from patients with PD. Our study highlights a mechanism of de novo α-Syn oligomerization at mitochondrial membranes and subsequent neuronal toxicity.

28 June 2024 in Science Advances
Verified
Journal Article
Open access
EGEmil K. Gustavsson
Emil K. Gustavsson
SSSiddharth Sethi
Siddharth Sethi
YGYujing Gao
Yujing Gao
JBJonathan W. Brenton
Jonathan W. Brenton
SGSonia García-Ruiz
Sonia García-Ruiz
MRMina Ryten
Mina Ryten
Mutations in GBA1 cause Gaucher disease and are the most important genetic risk factor for Parkinson’s disease. However, analysis of transcription at this locus is complicated by its highly homologous pseudogene, GBAP1 . We show that >50% of short RNA-sequencing reads mapping to GBA1 also map to GBAP1 . Thus, we used long-read RNA sequencing in the human brain, which allowed us to accurately quantify expression from both GBA1 and GBAP1 . We discovered significant differences in expression compared to short-read data and identify currently unannotated transcripts of both GBA1 and GBAP1 . These included protein-coding transcripts from both genes that were translated in human brain, but without the known lysosomal function—yet accounting for almost a third of transcription. Analyzing brain-specific cell types using long-read and single-nucleus RNA sequencing revealed region-specific variations in transcript expression. Overall, these findings suggest nonlysosomal roles for GBA1 and GBAP1 with implications for our understanding of the role of GBA1 in health and disease.

30 March 2020 in Brain Pathology
Verified
Journal Article
Open access
PDF file
SKShunsuke Koga
Shunsuke Koga
FLFuyao Li
Fuyao Li
NZNa Zhao
Na Zhao
SRShanu F. Roemer
Shanu F. Roemer
TFTanis J. Ferman
Tanis J. Ferman
DDDennis W. Dickson
Dennis W. Dickson
Background: Abnormal aggregates of α‐synuclein are pathologic hallmarks of multiple system atrophy (MSA) and Lewy body disease (LBD). LBD sometimes coexists with MSA, but the impact of co‐pathology, particularly diffuse LBD, on presentation of MSA has not been studied. We aimed to determine the frequency and clinicopathologic features of MSA with LBD (MSA+LBD). Methods: Using hematoxylin & eosin and α‐synuclein‐immunostained slides, we assessed the distribution and severity of LBD in 230 autopsy‐confirmed MSA patients collected from 1998 to 2018. Alzheimer‐type pathology was assessed to assign the likelihood of clinical presentations of dementia with Lewy body (DLB) using the consensus criteria for DLB. We reviewed medical records to characterize clinicopathologic features of MSA+LBD. Genetic risk factors for LBD, including APOE ε4 allele and mutations in GBA, SNCA, LRRK2, and VPS35, were analyzed. Results: LBD was observed in 11 MSA patients (5%); seven were brainstem type, three were transitional type, and one was diffuse type. The latter four had an intermediate or high likelihood of DLB. Three of the four had an antemortem diagnosis of Parkinson’s disease with dementia (PDD) or clinically probable DLB. Two patients had neuronal loss in the substantia nigra, but not in striatal or olivocerebellar systems with widespread glial cytoplasmic inclusions, consistent with minimal change MSA. In these cases, LBD was considered the primary pathology, and MSA was considered coincidental. APOE ε4 allele frequency was not different between MSA+LBD and MSA without LBD. Two of nine MSA+LBD patients had a risk variant of GBA (p.T408M and p.E365K). Conclusions: Although rare, MSA with transitional or diffuse LBD can develop clinical features of PDD or DLB. Minimal change MSA can be interpreted as a coincidental, but distinct, α‐synucleinopathy in a subset of patients with diffuse LBD.

1 August 2020 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
AWAnna I. Wernick
Anna I. Wernick
RWRonald L. Walton
Ronald L. Walton
SKShunsuke Koga
Shunsuke Koga
ASAlexandra I. Soto-Beasley
Alexandra I. Soto-Beasley
MHMichael G. Heckman
Michael G. Heckman
OROwen A Ross
Owen A Ross

14 February 2018 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
KOKotaro Ogaki
Kotaro Ogaki
YMYuka A. Martens
Yuka A. Martens
MHMichael G. Heckman
Michael G. Heckman
SKShunsuke Koga
Shunsuke Koga
CLCatherine Labbé
Catherine Labbé
OROwen A Ross
Owen A Ross

27 January 2021 in Clinical Autonomic Research
Verified
Journal Article
Closed access
PDF file
AWAnna I. Wernick
Anna I. Wernick
RWRonald L. Walton
Ronald L. Walton
ASAlexandra I. Soto-Beasley
Alexandra I. Soto-Beasley
SKShunsuke Koga
Shunsuke Koga
MHMichael G. Heckman
Michael G. Heckman
OROwen A Ross
Owen A Ross